Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant strides in recent years, positioning itself as a frontrunner in the industry.

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its ... system and the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) devices were able to reduce ...

Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

System* and the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device, respectively, during a late-breaking science session at AF Symposium 2025. Boston Scientific Corporation (NYSE ...

Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

One of the standout products in Boston Scientific's portfolio is the Watchman FLX Left Atrial Appendage Closure (LAAC) device. Recent clinical trial results from the OPTION study demonstrated the ...